MOFLAXY 0, 4 N5 ALOHA P

Nā papa hana ʻulaʻī.

1 papa pāahī-kiʻi e pili ana:
Kernel:
mea hana: moxifloxacin hydrochloride 454.75 mg, e like me moxifloxacin 400.00 mg,
nā mea waiwai: microcrystalline cellulose 186.05 mg, sodium croscarmellose 32.00 mg, magnesium stearate 6.00 mg,
He sheath Film: hypromellose 12.60 mg, macrogol-4000 4.20 mg, titanium dioxide (E171) 3.78 mg, dye iron oxide red (E172) 0.42 mg.

ʻO nā papa kākahi, nā papa biconvex, ʻōwiliʻeleʻele, ʻulaʻula.
Nānā i ka pae ʻāpana: nā aniani ākea ke aniani me ka kiʻi kiʻi o ke kala ʻulaʻula.

ʻĀpana Pharmacotherapeutic

antimicrobial aihue - fluoroquinolone

ICD-10:
X.J00-J06.J01 sinusitis huehue
X.J10-J18.J13 pneumoniae ka maʻi pneumoniae
X.J10-J18.J14 Nā maʻi maʻi maʻi e ka Haemophilus influenzae me Afanasyev-Pfeiffer stick
X.J10-J18.J15 Mea maʻi pneumonia kanalima, ʻaʻole ma kahi ʻē aʻe
X.J10-J18.J15.0 Ka maʻi pneumoniae Klebsiella
X.J10-J18.J15.7 Na wahi maʻi pneumoniae i hoʻoulu ʻia e ka Mycoplasma pneumoniae
X.J10-J18.J16.0 Nā pneumonia Chlamydia
X.J10-J18.J16.8 Pneumonia i hoʻoiho ʻia e nā mea maʻi ʻē aʻe o ka maʻi infectious
X.J20-J22.J20 Kahukui bronchitis
X.J20-J22.J20.1 Kahakaha hina ma muli o ka Haemophilus influenzae me Afanasyev-Pfeiffer lāʻau
X.J20-J22.J20.2 Kahakaha bronchitis ma muli o streptococcus
X.J20-J22.J20.8 Kaomi bronchitis ma muli o nā mea āpau i koho ʻia
X.J40-J47.J42 ʻOiola bronchitis, ʻike ʻole
XI.K65-K67.K65 Peritonitis
XII.L00-L08.L01 Impetigo
XII.L00-L08.L02 Ka nui o ka ʻili, hoʻolapalapa a me ka carbuncle
XII.L00-L08.L03 Phlegmon
XII.L00-L08.L08.0 Pyoderma
XII.L00-L08.L08.9 Hōʻailona kūloko o ka ʻili a me ke kiko subcutaneous, ʻaʻole i hoʻopuka

Lapaʻau lāʻau

Nā hana hana i ka hana
ʻO Moxifloxacin kahi pālahalaha bactericidal antibacterial lāʻau, 8-methoxy fluoroquinolone.
ʻO ka hopena bactericidal o moxifloxacin ma muli o ka like ʻana o ka bacterial topoisomerases II a me IV, ke alakaʻi nei i kahi e hoʻohauna ʻia o nā ʻōnaehana o ka hoʻoponopono ʻana, hoʻoponopono hou a me ka lawe ʻana i ka biosynthesis DNA o nā cell microbial a, ma muli o ka make ʻana o nā mikrobial cell.
Hoʻohālikelike ʻia nā hōʻuluʻulu o ka maʻi bactericidal o moxifloxacin e hoʻohālikelike ʻia i nā hoʻokaʻawale ʻana i nā mea paʻa.
Nā mīkini hana kū'ē
ʻO nā mīkini e alakaʻi i ka hoʻomohala ʻana i ke kūpaʻa o penicillins, cephalosporins, aminoglycosides, macrolides a me tetracyclines ʻaʻole i hoʻopilikia i ka hana antibacterial o moxifloxacin.
ʻAʻohe mea kū i ka pale ma waena o kēia mau pūʻulu o nā mea maʻi a me nā moxifloxacin. Ma kēia manawa, ʻaʻohe mau hihia o ka pale plasmid. ʻO ka liʻiliʻi o ka hoʻomohala ʻana o ka pale ʻana i ka liʻiliʻi (10-7-10-10).
Hoʻokumu maikaʻi ka pale ʻana ʻo Moxifloxacin i nā meʻa he maha. Hōʻike pinepine ʻia nā moxifloxacin i nā microorganism i loko o nā hoʻokili ma lalo o ka liʻiliʻi kukuna kukū (MIC) i ukali pū me ka liʻiliʻi iki o MIC. Kuhi ʻia nā hihia o ke kūʻē o ka quinolones. Eia naʻe, noho palupalu kekahi mau micro-positive a anaerobic kū'ē i nā quinolones ʻē aʻe i ka moxifloxacin.
Ua hoʻokumu ʻia ʻo ka hoʻohui o ka hui methoxy i ka molekui molekole moxifloxacin ma ke kūlana C8 i hoʻonui i ka hana o moxifloxacin a hōʻemi i ka hoʻokumu ʻana o nā mana mutant kūpaʻa o nā bacteria-maikaʻi. ʻO ka hoʻohui o ka hui bicycloamine ma ke kūlana C7 e pale i ka hoʻomohala ʻana o ka efflux ikaika, kahi hana kū'ē i nā fluoroquinolones.
I ka vitro moxifloxacin ka hana i ka pālahalaha nui o ka gram-Negative a me ka gram-positive microorganism, anaerobes, nā pale a ke kūpaʻa a me nā huapono atypical, e like me Mycoplasma spp., Chlamydia spp., Legionella spp., A me nā huakū ke kū nei nō naʻe? -Lactam a me ka macrolide antibiotic.
Ka hopena i ka microflora pēpē kanaka
I loko o nā haʻawina ʻelua i hana ʻia ma luna o nā mea hana, hiki ke ʻike ʻia nā loli e like me nā microflora o ka ʻōpū ma hope o ke alakaʻi ʻana o ka moxifloxacin. ʻO ka emi ʻana o nā ʻaina o Escherichia coli, Bacillus spp. ʻO nā Bacteroides vulgatus, Enterococcus spp., Klebsiella spp., A me nā anaerobes Bifidobacterium spp., Eubacterium spp., Peptostreptococcus spp. Ua hoʻololi ʻia kēia mau loli i loko o nā pule ʻelua. ʻAʻole i ʻike ʻia ka mea momona Clostridium.

Lapaʻau lāʻau

I ka wā e lawelawe ʻia, ke hoʻomoʻi nui ʻia ka moxifloxacin a kokoke loa. ʻO ka bioavailability piha e pili ana i ka 91%.

ʻO ka pharmacokinetics o moxifloxacin i ka wā i lawe ʻia ma ke ʻano o 50 ma 1200 mg hoʻokahi, me ka 600 mg / lā no 10 lā, he laina. Loaʻa ka manawa kūloko i loko o 3 mau lā.

Ma hope o kahi noi hoʻokahi o 400 mg o moxifloxacin Cmax i loko o ka plasma koko i loaʻa i loko o nā hola 0.5-4 mau hola a ʻo 3.1 mg / L. Ma hope o ka hoʻoponopono waha waha he 400 mg o moxifloxacin 1 ka manawa i kēlā me kēia lā, Cssmax a me Cssmin (ka nui a me ka haʻahaʻa kūpaʻa kaulike) ʻo 3.2 mg / l a me 0.6 mg / l, ma ia mea.

Ke lawe ʻoe i ka moxifloxacin me ka meaʻai, he liʻiliʻi iki i ka manawa e hōʻea ai i Cmax (e 2 mau hola) a me kahi emi iki i Cmax (e pili ana i 16%), ʻoiai ka loli ka lōʻihi o ka absorption. Eia naʻe, ʻaʻole pili kēia mau ʻikepili i ka pili, a hiki ke hoʻohana ʻia nā moxifloxacin e pili ana i ka manawa o ka pāʻina.

Hoʻopuka koke ʻia ʻo Moxifloxacin i loko o nā palu a me nā ʻāpana a hoʻopaʻa i nā protein plasma koko (ʻo ka mea nui ka albumin) ma kahi o 45%. ʻO ka nui o ka hoʻonuiʻana e pili ana i 2 l / kg.

ʻO nā mea nui o ka moxifloxacin, ma mua o ka mea pili i ka plasma koko, i hoʻokumu ʻia i loko o ka ʻōpū o ka pūpū (me nā hua epithelial, alveolar macrophages), i nā sinus paranasal (maxillary a me ka laboithmomoid), i nā polips nasal, i ka foci o ka mumū (i loko o nā kiko o nā blisters no nā ʻili o ka ʻili). ) I ka wai kai interstitial a me ka wai kai, ua hoʻoholo ʻia ka moxifloxacin i kahi ʻano manuahi ʻole, ʻaʻole i hoʻopaʻa ʻia nā protein, ma kahi hoʻokūkū kiʻekiʻe ma mua o nā kaila koko. Eia kekahi, ʻike ʻia nā kiʻekiʻe kiʻekiʻe o ka moxifloxacin i loko o nā kiko o nā ʻōpū o ka ʻōpū, peritoneal fluid, a me nā kāne o nā kāne.

Moxifloxacin e hana ana i ka biotransformation o ka lā 2 a ua lawe ʻia mai ke kino e nā ʻōpū, a me ka hiki ʻana i nā ʻāpana, ʻaʻole i loli a ma ke ʻano o ka pūhui sulfo inactive (M1) a me glucuronides (M2). ʻAʻole ke kaha nā Moxifloxacin e ka ʻōnaehana mikrosomal cytochrome P450. Aia ka Metabolites M1 a me M2 i ka plasma koko i loko o kaʻili o lalo ma mua o ka pūnao makua. Wahi a nā hopena o nā noi preclinical, ua hōʻike ʻia ʻaʻole i loaʻa ka hopena maikaʻi loa o kēia mau metabolite i ke kino ma ke ʻano o ka palekana a me ka hoʻomau.

ʻO ka hapalua hapalua o moxifloxacin he 12 mau hola. Ka awelika helu maʻa ma hope o ka hoʻokele ʻana ma kahi maʻa o 400 mg ʻo 179-246 ml / min. ʻO ka wehe Renal ʻo 24-53 ml / min. Hōʻike kēia i ka ʻāpana pūhaka reabsorption o moxifloxacin.

ʻO ka kaulike nui o ka pūhui hoʻomaka a me nā mea hoʻoneʻe o ka hoʻolālā o ka 2 ma kahi o 96-98%, e hōʻike ana i ka haʻalele ʻana o nā mea hoʻonā oxidative. Ma kahi o 22% o hoʻokahi pākahi (400 mg) ka excreted i hoʻololi ʻole ʻia e nā keiki, ma kahi o 26% - ma o nā ʻōpū.

Pharmacokinetics i loko o nā hui hoʻomanawanui

ʻO ka makahiki, ke kāne a me ka lāhui

ʻO kahi hōʻike o ka pharmacokinetics o moxifloxacin i nā kāne a me nā wahine i hōʻike i nāʻokoʻa o 33% ma nā ʻōlelo o AUC a me Cmax. ʻAʻole i hilinaʻi ʻia ka pale ʻana o ka moxifloxacin i ka male. ʻO nā ʻokoʻa ma AUC a me Cmax ma muli o kahiʻokoʻa o ka paona ma mua o ka wahine a ʻaʻole i manaʻo ʻia he koʻikoʻi ʻoi aku.

ʻAʻohe kūlike koʻikoʻi i nā maʻi i ka pharmacokinetics o moxifloxacin i nā mea maʻi o nā ʻohana ʻē aʻe o nā ʻano like ʻole.

ʻAʻole i aʻo ʻia nā pharmacokinetics o moxifloxacin i nā keiki.

Hola paʻa kino hana

I loko, 1 papa (400 mg) 1 manawa i kēlā me kēia lā me nā maʻi i hōʻike ʻia ma luna.

Mai pā i ke ʻano momona.

E hoʻopau ʻia nā papa āpau, me ka hika ʻole, me ka nui o ka wai, me ka ʻole o ka manawa ʻaina.

Hoʻoholo ʻia ka lōʻihi o ka mālama ʻia e ke wahi a me ka hōʻeha o ka maʻi, me ka hopena hopena ma ke ʻano:

- ka mea e ulu ana i ka maʻi bronchitis: 5-10 lā,

- ka maʻi sinusitis: 7 lā,

- nā maʻi kīnā ʻole o ka ʻili a me ka hoʻolālā kino. 7 lā,

- nā maʻi pona no ka kaiāulu: ʻo ka loa o ka lōʻihi o ka hiki ʻana i ka laikini (ka hana intravenous me ka hoʻoponopono waha o hope) ʻo 7-14 lā,

- nā hōʻeha ʻeha o nā ʻili a me nā hana ʻolopoli: ʻo ka nui o ka lōʻihi o ka therapy stepwise me moxifloxacin (ka hana intravenous me ka waha o ka waha) a 7-7 lā,

- nā maʻi ʻeha intra-abdominal: ʻo ka nui o ka lōʻihi o ka hiki ʻana i ka laikini (ka hana intravenous me ka waha waha o hope) ʻo 5-14 lā,

- Nā maʻi maʻi hoeha ʻole i nā hanana pelvic: 14 mau lā.

ʻAʻole iʻoi aku i ka lōʻihi o ka mālama ʻia.

Wahi a nā haʻawina loea, hiki i ka lōʻihi o ka mālama ʻana me Moflaxia i nā papa ke hiki i 21 lā.

ʻO nā maʻi maʻi

ʻAʻole pono ke hoʻololi ʻana i ka hoʻoponopono ʻia i ka poʻe maʻi maʻi.

ʻAʻole paʻa ka hopena a me ka palekana o ka hoʻohana ʻana o ka moxifloxacin i nā keiki a me nā ʻōpio.

Hōʻeha ka hana ʻoluʻolu

ʻO nā mea maʻi me ka hana ʻōiwi lēwa (ka papa helu papa keiki-Pugh A a me B) ʻaʻole pono e hoʻololi i ka hoʻoponopono dosage (no ka hoʻohana ʻana i nā maʻi me ka cirrhosis, e ʻike i ka mahele "Mahele ʻAʻao Kūlana").

Hola paʻa kino hana

I ka poʻe maʻi me ka hana renal impaired (me ka nui o ka maikaʻi ʻole o ka renal me CC

E hoʻokuʻu i nā palapala a me ka ʻano

Loaʻa ka lāʻau lapaʻau i kahi palapala papa. Aia i hoʻokahi papa liʻiliʻi ma kahi o 400 mg o ka hana nui - moxifloxacin hydrochloride. Eia kekahi, ʻo ka hoʻonohonohoʻana o ka lāʻau e komo ai i ka macrogol, titanium dioxide, hypromellose, lepo. Aia nā papa i kahi ʻano capsular biconvex. Ua uhi ʻia lākou me kahi pālahalaha kiʻi ʻulaʻula. Hoʻopili ʻia nā papa Moflaxia i nā pōpō o 5, 7 a i ʻole 10 mau pcs. Hoʻopili ʻia nā pani ma nā kāla pepa. ʻAʻole i loaʻa ka lāʻau lapaʻau i ke ʻano o kahi hopena no ka hoʻomehana intramuscular a intravenous.

Loaʻa ka lāʻau lapaʻau i kahi palapala papa.

Ka hana lāʻau lapaʻau

ʻO ka mea hana a Moflaxia e pili ana i ka pūʻulu o nā fluoroquinolones, no laila aia kahi hopena antibacterial i ka pālahalaha o nā microorganism pathogenic. ʻO ka hana o ka lāʻau lapaʻau ma muli o ke hiki ke hoʻokahe i ka mea ikaika o ka hoʻomākaukau ʻana o ka topoisomerases bakteria o nā momo 2 a me 4, ma muli o ke ʻano o ka maʻi biosynthesis DNA e kūleʻa ʻia i nā kōna o nā microorganism pathogenic, e alakaʻi ana i ka make o nā huakini.

Hoʻopili ka waiwai ikaika o Moflaxia i nā microorganisms maikaʻi a maikaʻi loa-gram a me ka lāʻau. Eia kekahi, pono ka lāʻau i nā ʻano kūaloko o nā microflora pathogenic.

Nā hōʻailona no ka hoʻohana ʻana

Hiki i kēia lāʻau lapaʻau ke kuhikuhi no ka nui o nā maʻi o ka ʻano maʻi, ka hele pū ʻana me ka maʻi ʻino. Nohea ʻia e hoʻohana i ka lāʻau lapaʻau wale nō inā hōʻoia ka mea maʻi i ka hiki ʻana o ka microflora sensity i Moflaxia. ʻO nā maʻi no ka hoʻohana ʻana i ka lāʻau lapaʻau ka maʻi sinusitis koʻikoʻi.

Hoʻomaopopo ʻia ka lāʻau lapaʻau no ka hoʻohana ʻana ma nā exacerbations o ke ʻano maʻamau o ka bronchitis. Koho ʻia ka Moflaxia e ʻae ʻia i ka mālama ʻia ʻana o nā maʻi ʻili o kahi ʻano maʻi e kū nei me ka ʻole o nā hōʻailona o ke kuni ʻana. Hoʻohana ʻia ka hoʻohana ʻana o Moflaxia no nā pahuhopu therapeutic i ka mālama ʻana i ka pneumonia i loaʻa i nā kaiāulu, e komo pū me nā mea i kūlaʻi ʻia e nā maʻi a nā microorganism.

ʻO kahi mahele i kahi lāʻau lapaʻau holoʻokoʻa, ke noi aku nei kēia lāʻau lapaʻau e kuhikuhi ʻia no ka sinusitis. Hiki i ke Moflaxia kaupalena ke hoʻohana ʻia no nā maʻi paʻakikī o ka ʻili. Me kēia lāʻau lapaʻau, hiki iā ʻoe ke mālama i ka wāwae maʻi maʻi, paʻakikī i ka hoʻohui ʻana o kahi maʻi maʻi lua.

ʻO nā ʻōmaka no ka hoʻohana ʻana i ka lāʻau lapaʻau he intra-abdominal abscess a me ka paʻakikī paʻakikī intra-abdominal. Hoʻohana ʻia ka hoʻohana ʻana o Moflaxia i ka mālama ʻana i nā maʻi ʻoi ʻana o ka ʻōnaehana hānau wahine. Eia kekahi, hiki ke hoʻohana ʻia ka lāʻau lapaʻau no ka prostatitis o kahi ʻanoʻeha.

Nā Hoʻohui

Hoʻohana ʻia ka hoʻohana ʻana o Moflaxia me ka hypersensitivity i nā mea ikaika o ka lāʻau. Eia kekahi, ʻaʻole i kuhikuhi ʻia kēia lāʻau lapaʻau no nā poʻe maʻi e loaʻa nei i ka mōʻaukala o nā pathologies tendon i hōʻea i ka wā o ka maʻi me ka quinolone antibacterial drug.

ʻAʻole kuhikuhi ʻia ka lāʻau lapaʻau no nā poʻe me ka paʻakikī o ka naʻau.

ʻO nā hoʻohālikelike no ka hoʻohana ʻana i ka lāʻau lapaʻau nā mea hoʻonāukiuki electrolyte, i hele pū ʻia e ke ʻano o ka hypokalemia, ʻaʻole ʻae ʻia e hoʻoponopono. ʻO nā hoʻohālikelike no ka hoʻohana ʻana i ka lāʻau lapaʻau nā hōʻeuʻeu o ka rdy a me ka bradycardia. ʻAʻole ia e kau ʻia ka lāʻau lapaʻau a inā he mau maʻi ke hōʻailona o ka hiki ʻole o ka puʻuwai naʻau.

Me ka mālama pono

Me ka makaʻala nui, ua kuhikuhi ʻia kēia lāʻau lapaʻau i nā mea maʻi me nā ala CNS, i ukali ʻia e ka nānā ʻana i nā lawe. Pono ka nānā koʻikoʻi o ke kūlana o ka mea maʻi e nā limahana lapaʻau e pono inā loaʻa ka maʻi noʻonoʻo.

Eia kekahi, pono e hoʻohana ʻia ka lāʻau lapaʻau me ka mālama pono ʻana i ka mālama ʻana i nā mea maʻi e loaʻa ana i ka maʻi puʻuwai coronary a me ka mōʻaukala o ka hopu ʻana i ka puʻuwai. ʻO ka lāʻau Moflaxia no nā poʻe maʻi me ka cirrhosis e pono e lawe ma lalo o ka nānā o kahi loea. Ma kēia māhele o ka poʻe maʻi, ua hoʻonui ʻia ka hopena o ka hoʻoulu ʻana i nā hopena a me ka hoʻonui i ka papa o ke ʻano pathological i nā manawa.

Me ka mālama nui, hāʻawi ʻia kēia lāʻau lapaʻau i ka poʻe maʻi me nā ala CNS.

Pehea e lawe ai i Moflaxia

Pono ʻia kēia lāʻau lapaʻau no ka hoʻohana ʻana i loko. I ka mālamaʻana i nā maʻi lēʻeha e hōʻeuʻeu e nā maʻi i hoʻoweliweli ʻia i ka hana a ke ʻano ikaika o Moflaxia, pono e lawe ʻia kēia lāʻau lapaʻau ma kahi o ka 400 mg (1 papa) i hoʻokahi lā. E hoʻopau ʻia ka papa papaʻa ʻole me ka ʻōlohelohe, a pono e inu ia me ka wai. No ka hoʻokō ʻana i kahi hopena therapeutic i loko o nā kuʻuna infectious loa, ʻo ka lawe ʻana i ka lāʻau lapaʻau no 5-7 lā ua lawa. Me ka maʻi kūlohelohe o ka ʻili a me ka puʻu ʻōpū, ʻo ke ʻano o ka mālama ʻana mai ka 14 a hiki i ka 21 lā.

Lawe i ka lāʻau lapaʻau no ka maʻi maʻi maʻi

ʻO nā mea maʻi me ka maʻi mellitus e kuhikuhi ʻia i ka lāʻau lapaʻau ma kahi ʻelua o 400 mg i kēlā me kēia lā, akā pono e nānā pono ʻia ka nui o ka glucose koko.

ʻO nā maʻi me ka maʻi maʻi, hoʻolaʻa ʻia ka lāʻau lapaʻau ma loko o kahi kaha o 400 mg i kēlā me kēia lā.

ʻŌpala Gastrointestinal

Ka loaʻa ʻana o ka Moflaxia ka hopena kūpono ma ka hāhai ʻana o ka huina a ke kumu o ka hoʻololi ʻana i ka microflora pono o ka ʻōpū, e hoʻonui ana i ka hopena o ka hopena mai ka hoʻopili ʻana. Wahi a nā data klinika, ʻo ka hapa nui o nā mea maʻi ma hope o ka lawe ʻana i ka Moflaxia loaʻa kahi hoʻopiʻi o ka maʻi, nā maʻi hōʻeha a me nā ʻeha ʻeha. Hoʻololi pinepine ʻia me ka Moflaxia therapy, kahi i hoʻemi ʻia ka nui o ka momona. Eia kekahi, ʻo ka hoʻomohala ʻana o ka flatulence a me ka dyspepsia hiki. I nā hanana ka hopena, ʻo ka stomatitis, ka maʻi o ka erosive, ka dysphagia, a me ka colitis e kū ana i ka wā o ka mālama ʻana me ka lāʻau lapaʻau.

Pūnaehana pīhoihoi waena

ʻO ka mālamaʻana iā Moflaxia, hiki i ke ʻano o nā maʻi noʻonoʻo o ka maʻi, i hōʻike ʻia e ka piʻi ʻana o ka psychomotor agitation a me ke kaumaha. Loaʻa kekahi mau maʻi i ka kaumaha a me ka hana naʻau. Hiki ke hoʻōla ʻia nā hālāwai hoʻokipa a me nā moe.Me ka maʻi Moflaxia, hiki i ka ʻeha a me ke poʻo. Hiki i nā mea hoʻonāukiuki i loko o ka ʻike ʻana o ka ʻono a me ka ʻono, dysesthesia, paresthesia a me peripheral polyneuropathy.

Mai ka pūnaehana cardiovascular

Ke hoʻohana nei ʻo Moflaxia, tachycardia hōʻeuʻeu, lele i loko o ke koko a me nāwaliwali ma muli o ka hōʻino ʻana o ka ʻōnaehana cardiovascular hiki.

I ka manawa e hoʻohana ai iā Moflaxia, e kū mai ka tachycardia a lele i loko o ke kō koko.

Mai ka musculoskeletal a me ka hoʻopili pili

E kū'ē i ke kua o ke lawe ʻana i ka lāʻau lapaʻau, hiki i ka hiʻohiʻona o myalgia a me ka arthralgia. I kekahi mau mea maʻi, ua nānā ʻia ka leo mānoanoa a me nā mākeke. Puhi ka Tendon a me ka hoʻomohala ʻana i ka ʻōpū o ka haki ʻana i ʻike pinepine ʻole ʻia.

Ma ka hoʻomaʻamaʻa ʻana o Moflaxia, hiki mai paha nā hopena kūlohelohe, i hōʻike ʻia e like me ka ʻāʻī o ka ʻāʻī, kaʻeha, a me ka urticaria. I nā hihia pinepine, hiki i ka angioedema a me ke anaphylaxis.

Ke noi no ka hana lawelawe lēʻaleʻa

I nā hihia o ka hana o ka puʻuwai a me ka hana ʻole o ka ate, hiki i ka Moflaxia ke hoʻohana e mālama i nā maʻi, akā ʻo nā mea maʻi me nā ala āpau e koi i ka mālama kūikawā e nā limahana olakino.

Me ka hana pūpū paʻa ʻole a me ka hiki ʻana o ka nānā ʻole o ka ate, hiki i ka Moflaxia ke hoʻohana e mālama i nā maʻi.

Hoʻopili pū me nā lāʻau ʻē aʻe

Me ka hoʻohana ʻana o ka Moflaxia me Warfarin, ʻaʻole i ʻike ʻia nā maʻi pili koko. Hoʻohana ʻia ka hoʻohana pinepine ʻana o Moflaxia me nā antidepresi tricyclic, antipsychotics, antiarrhythmics a me nā antihistamines. ʻAʻole ia e hāʻawi i hoʻohui i ka hoʻohana ʻana o Moflaxia me nā meaola a pau. ʻO ka hoʻohana like ʻana o Moflaxia me nā antacids e kōkua i ka hōʻemi o ka pono o nā pika. Hōʻemi ka carbon carbon i ka hana pono o ka pono o ka lāʻau.

ʻAʻole ia e hāʻawi i hoʻohui i ka hoʻohana ʻana o Moflaxia me nā meaola a pau.

Hoʻolaha ka waipuna

Ke hoʻokomo nei i ka lāʻau antibiotic me Moflaxia, pono ʻoe e hōʻole i ka inu ʻona.

Nui nā lāʻau lapaʻau e hiki ke hana e like me nā mea i hoʻololi ʻia no Moflaxia, e pili pū i:

ʻO Avelox kekahi o nā kaona o Moflaxia.

Hōʻike Moflaxia

Irina, 32 makahiki, Chelyabinsk

Hoʻohana wau iā Moflaxia me nā exacerbations o bronchitis. Ua maʻi ʻia kēia maʻi ma koʻu ʻano a ua hōʻike ʻia kēlā mau mahina 2-3 e nā maʻi ʻeha. Hoʻohana wau iā Moflaxia no 2-3 mau lā a hāʻule ʻole nā ​​hōʻailona a pau. ʻAʻole hoʻopau koke ka lāʻau lapaʻau i nā hōʻike o ka maʻi, akā ʻaʻole pū kekahi iaʻu i nā hopena ʻaoʻao. Hoʻolālā wau e hoʻomau i ka hoʻohana ʻana i kēia lāʻau lapaʻau.

Maxim, 34 makahiki, Moscow

Ma kahi paha hoʻokahi makahiki i hala aku nei, ua hāʻule i ka ua a ke hoʻi ʻo ia i ka hale i hele ai ʻo ia e moe, ʻaʻole e hoʻomaʻemaʻe piha i kona lauoho. I ke kakahiaka ua manaʻo au i ke kaumaha ma loko o ka maka a me kahi hōʻeha koʻikoʻi. ʻAʻole hiki ke pale ʻia kēlā ʻano, no laila ua hele koke au i ke kauka i hōʻike ʻia me ka sinusitis aʻalohi. Ua kuhikuhi ke kauka iā Moflaxia. Ua hoʻohana ʻia kēia lāʻau lapaʻau no 2 pule. Ua manaʻo wau i ka holomua ma ka lua o ka lā, akā hoʻoholo ia e holo i ke papa i ka hopena, makaʻu ʻana i nā hoʻopiʻi ʻana. Hāʻawi ka lāʻau lapaʻau i ka hopena maikaʻi.

Kristina, 24 makahiki, Sochi

Ma kahi o hoʻokahi makahiki i hala aku nei ua hopu ʻo ia i kahi anu. I ka wā mua, ʻoiai ka maʻi maʻi, ʻaʻole au i hoʻolohe iki iā ia, akā a laila hoʻomaka ka ʻano o ka maʻule, no laila, pono wau e kāhea i kahi ʻāpana. Ua hōʻike ka haukapila i ka maʻi pneumonia. Ma ke kauoha a ke kauka, hoʻomaka ʻo ia e lawe iā Moflaxia. Ma hope o ka hoʻomaka ʻana i ka lāʻau lapaʻau, ua loaʻa iaʻu kahi maʻi iki. ʻAʻole i hōʻole ka lāʻau i ka lawe ʻana mai a ma hope o kekahi mau lā ua ʻike maikaʻi au. Ua hele wau i kahi papa hana o ka mālama ʻana, ka mea i hala iā 14 mau lā, a ua hauʻoli wau i ka hopena.

Igor, 47 makahiki, Saint Petersburg

E ʻike i kou pilikia no ka hoʻomohala ʻana i ka maʻi diabetes!

Lawe i kahi hōʻike hoʻokolohua manuahi mai nā endocrinologists ʻike

ʻO ka wā hoʻāʻo ʻana ʻaʻoleʻoi aku ma mua o 2 mau minuke

7 a maʻalahi
o nā pilikia

94% pololei
hoʻāʻo

10 tausani ka pōmaikaʻi
hoʻāʻo

Ua maʻi au i ka diabetes mellitus a inā wau e mālama pono ana i kahi papaʻai a kaohi i ke kiʻekiʻe o ke kō, hū ʻia kahi ulia trophic ma koʻu wāwae, ka mea i hoʻonui nui ʻia i ka nui a ke hoʻomake nei. E like me ke kauka ʻana e ke kauka, hoʻohana ʻo ia i Moflaxia ma ke ʻano o ka ʻoihana paʻakikī. Ua kōkua nui ka mea kōkua. Holo ka nahu iā fester no nā lā he nui a hoʻomaka ka hōʻola. Ua hoʻohana au i ka antibiotic i 14 lā. ʻAʻole pili i nā hopena ʻaoʻao.